Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 9/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15664132 | 0.86 | KMT2A (0.48) | TNFALDH1A1HSD17B10L3MBTL1PDE4A | |
| SCHEMBL19053750 | 0.83 | TNF (0.44) | TNFHDAC7PDE4APDE4BPDE4C | |
| SCHEMBL10318765 | 0.83 | UTS2R (0.53) | TNFHDAC7PDE4APDE4BPDE4C | |
| SCHEMBL16690783 | 0.83 | UTS2R (0.53) | TNFHDAC7PDE4APDE4BPDE4C | |
| SCHEMBL15663593 | 0.82 | TNF (0.46) | TNFALDH1A1HSD17B10L3MBTL1PDE4A | |
| SCHEMBL16679652 | 0.78 | TNF (0.46) | TNFHDAC7ALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL15664047 | 0.78 | ALDH1A1 (0.45) | TNFALDH1A1HSD17B10L3MBTL1PDE4A | |
| SCHEMBL28076631 | 0.77 | TNF (0.55) | TNFHDAC7PDE4APDE4BPDE4C | |
| SCHEMBL16692506 | 0.76 | TNF (0.50) | TNFHDAC7PDE4APDE4BPDE4C | |
| SCHEMBL17611118 | 0.76 | SMN1; SMN2 (0.46) | TNFALDH1A1HSD17B10L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10188649-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| EP-3063143-B1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-05-16 | — | — | EP | disclosed |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-9763937-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| EP-3063143-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| CN-105658646-A | Aminoheteroaryl benzamides as kinase inhibitors | 诺华股份有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-9242996-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| WO-2015066188-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885HDAC7 345/4885ALDH1A1 2959/4885 |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885HDAC7 345/4885ALDH1A1 2959/4885 |
| US-10188649-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885HDAC7 345/4885ALDH1A1 2959/4885 |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885HDAC7 345/4885ALDH1A1 2959/4885 |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885HDAC7 345/4885ALDH1A1 2959/4885 |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | TNF 4598/4885HDAC7 345/4885ALDH1A1 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.